KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Other Accumulated Expenses: 2017-2025

Historic Other Accumulated Expenses for Moderna (MRNA) over the last 7 years, with Sep 2025 value amounting to $73.0 million.

  • Moderna's Other Accumulated Expenses rose 5.80% to $73.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.0 million, marking a year-over-year increase of 5.80%. This contributed to the annual value of $221.0 million for FY2024, which is 71.32% up from last year.
  • Per Moderna's latest filing, its Other Accumulated Expenses stood at $73.0 million for Q3 2025, which was down 61.98% from $192.0 million recorded in Q2 2025.
  • Moderna's 5-year Other Accumulated Expenses high stood at $613.0 million for Q2 2021, and its period low was $42.0 million during Q2 2024.
  • Its 3-year average for Other Accumulated Expenses is $168.6 million, with a median of $192.0 million in 2025.
  • As far as peak fluctuations go, Moderna's Other Accumulated Expenses spiked by 7,213.29% in 2021, and later slumped by 82.20% in 2024.
  • Quarterly analysis of 5 years shows Moderna's Other Accumulated Expenses stood at $225.0 million in 2021, then climbed by 10.67% to $249.0 million in 2022, then crashed by 48.19% to $129.0 million in 2023, then surged by 71.32% to $221.0 million in 2024, then increased by 5.80% to $73.0 million in 2025.
  • Its Other Accumulated Expenses stands at $73.0 million for Q3 2025, versus $192.0 million for Q2 2025 and $252.0 million for Q1 2025.